Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Link opens in a new tab
Search content at UTMB Health Research Expert Profiles
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Therapeutic silencing of KRAS using systemically delivered siRNAs
Chad V. Pecot
, Sherry Y. Wu
, Seth Bellister
, Justyna Filant
, Rajesha Rupaimoole
, Takeshi Hisamatsu
, Rajat Bhattacharya
, Anshumaan Maharaj
, Salma Azam
, Cristian Rodriguez-Aguayo
, Archana S. Nagaraja
, Maria Pia Morelli
, Kshipra M. Gharpure
, Trent A. Waugh
, Vianey Gonzalez-Villasana
, Behrouz Zand
, Heather J. Dalton
, Scott Kopetz
, Gabriel Lopez-Berestein
, Lee M. Ellis
Anil K. Sood
Show 1 others
Show less
Research output
:
Contribution to journal
›
Article
›
peer-review
88
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Therapeutic silencing of KRAS using systemically delivered siRNAs'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Small Interfering RNA (siRNA)
100%
Knockdown
22%
Tumor Growth
22%
Treatment Group
22%
Lung Cancer Model
22%
CDDP
22%
Colon Cancer Model
22%
Systemic Delivery
11%
Antiproliferative Activity
11%
Liver Metastasis
11%
Therapeutic Potential
11%
Human Cancer
11%
Tumor
11%
Metastasis
11%
Oncology
11%
RNA Interference
11%
Delivery Platform
11%
RNA Therapy
11%
Oncogene
11%
Growth Development
11%
Downstream Signaling
11%
Caspase-3 Activity
11%
Distant Metastasis
11%
Mutant Cell Line
11%
Subcutaneous Tumor
11%
Colorectal Adenocarcinoma Cells
11%
Adenocarcinoma Cells
11%
Clinical Option
11%
In Vivo Experiment
11%
Ki-67 Index
11%
Cancer Model
11%
Hcp1
11%
Lung Adenocarcinoma Cells
11%
Nanoparticle Delivery
11%
RNA Therapeutics
11%
Undruggable Targets
11%
Nanoliposomal
11%
Translational Impact
11%
Primary Tumor Growth
11%
Medicine and Dentistry
Small Interfering RNA
100%
Cancer Model
40%
Tumor Progression
30%
Metastatic Carcinoma
20%
Lung Cancer
20%
Colon Carcinoma
20%
Treatment Group
20%
Malignant Neoplasm
10%
Neoplasm
10%
In Vitro
10%
Cell Line
10%
Antiproliferative Activity
10%
Liver Metastasis
10%
Oncology
10%
Primary Tumor
10%
Oncogene
10%
Caspase 3
10%
Colon Adenocarcinoma Cell Line
10%
Cell Mutant
10%
Lung Adenocarcinoma Cell Line
10%
RNAi Therapeutics
10%
Nanoparticle
10%
Pharmacology, Toxicology and Pharmaceutical Science
Small Interfering RNA
100%
Cancer Model
40%
Tumor Growth
30%
Lung Cancer
20%
Colon Carcinoma
20%
Treatment Group
20%
Malignant Neoplasm
10%
Liver Metastasis
10%
Neoplasm
10%
Primary Tumor
10%
Caspase 3
10%
Nanoparticle
10%
Lung Adenocarcinoma
10%
Colon Adenocarcinoma
10%